NASDAQ:CDNA CareDx (CDNA) Stock Price, News & Analysis $27.10 -0.03 (-0.11%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$26.18▼$27.5050-Day Range$14.41▼$33.9952-Week Range$4.80▼$34.84Volume654,780 shsAverage Volume914,666 shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$28.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CareDx alerts: Email Address CareDx MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside6.3% Upside$28.80 Price TargetShort InterestHealthy6.49% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.70Based on 8 Articles This WeekInsider TradingSelling Shares$3.03 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.84) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.47 out of 5 starsMedical Sector284th out of 910 stocksMedical Laboratories Industry11th out of 18 stocks 2.2 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageCareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CareDx's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.49% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CareDx has recently decreased by 7.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 3.2 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CareDx this week, compared to 3 articles on an average week.Search Interest11 people have searched for CDNA on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,025,415.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders.Read more about CareDx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($0.84) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CareDx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About CareDx Stock (NASDAQ:CDNA)CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesAugust 23, 2024 | insidertrades.comInsider Selling: CareDx, Inc (NASDAQ:CDNA) Insider Sells 21,557 Shares of StockAugust 22, 2024 | insidertrades.comCareDx, Inc (NASDAQ:CDNA) Insider Sells $1,148,450.05 in StockSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 7 at 6:59 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Upgraded by StockNews.com to BuySeptember 3, 2024 | americanbankingnews.comCareDx, Inc (NASDAQ:CDNA) Receives Consensus Rating of "Hold" from BrokeragesAugust 30, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Cut to "Hold" at StockNews.comAugust 29, 2024 | msn.comWells Fargo Initiates Coverage of CareDx (CDNA) with Underweight RecommendationAugust 29, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Now Covered by Wells Fargo & CompanySeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 28, 2024 | americanbankingnews.comCareDx, Inc (NASDAQ:CDNA) Insider Sells $702,327.06 in StockAugust 28, 2024 | americanbankingnews.comPeter Maag Sells 35,552 Shares of CareDx, Inc (NASDAQ:CDNA) StockAugust 26, 2024 | msn.comCareDx (CDNA) Surged Due to Positive Testing Volume GrowthAugust 20, 2024 | markets.businessinsider.comPositive Outlook for CareDx: Anticipating Revenue Growth and Manageable Legal ChallengesAugust 20, 2024 | msn.comBTIG Upgrades CareDx (CDNA)August 19, 2024 | msn.comApple, Lineage, OneStream initiated: Wall Street's top analyst callsAugust 17, 2024 | stockhouse.comCareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap TestingAugust 6, 2024 | msn.comCareDx, Inc (CDNA): Among the Best Organ Transplant and Diagnosis Stocks to Buy According to Hedge Funds?August 5, 2024 | finance.yahoo.comAnalysts Just Made A Substantial Upgrade To Their CareDx, Inc (NASDAQ:CDNA) ForecastsSee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees740Year FoundedN/APrice Target and Rating Average Stock Price Target$28.80 High Stock Price Target$40.00 Low Stock Price Target$18.00 Potential Upside/Downside+6.3%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,280,000.00 Net Margins-53.73% Pretax Margin-53.73% Return on Equity-53.65% Return on Assets-33.44% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio3.85 Sales & Book Value Annual Sales$297.08 million Price / Sales4.75 Cash FlowN/A Price / Cash FlowN/A Book Value$5.02 per share Price / Book5.40Miscellaneous Outstanding Shares52,084,000Free Float49,896,000Market Cap$1.41 billion OptionableOptionable Beta1.78 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Abhishek Jain (Age 47)CFO & Principal Accounting Officer Comp: $425.58kDr. Peter Maag Ph.D. (Age 57)Executive Director Comp: $43.23kMr. Alexander L. Johnson (Age 50)President of Patient & Testing Services Comp: $547.43kMr. John Walter Hanna Jr. (Age 44)President, CEO & Director Ms. Marica Grskovic Ph.D.Chief Operating OfficerDr. Robert N. Woodward Ph.D.Chief Scientific OfficerMr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerJeffrey A. NovackGeneral CounselMs. Stacey FollonSenior VP & Head of Human ResourcesMr. Kashif RathoreChief of Patient & Digital SolutionsMore ExecutivesKey CompetitorsGenetronNASDAQ:GTHBurning Rock BiotechNASDAQ:BNRRadNetNASDAQ:RDNTOption Care HealthNASDAQ:OPCHSotera HealthNASDAQ:SHCView All CompetitorsInsiders & InstitutionsAlexander L JohnsonSold 21,557 sharesTotal: $702,327.06 ($32.58/share)Peter MaagSold 35,552 sharesTotal: $1.17 M ($33.04/share)Alexander L JohnsonSold 34,231 sharesTotal: $1.15 M ($33.55/share)Driehaus Capital Management LLCBought 183,613 shares on 8/16/2024Ownership: 0.353%Millennium Management LLCBought 1,960,308 shares on 8/15/2024Ownership: 4.110%View All Insider TransactionsView All Institutional Transactions CDNA Stock Analysis - Frequently Asked Questions How have CDNA shares performed this year? CareDx's stock was trading at $12.00 at the beginning of the year. Since then, CDNA shares have increased by 125.8% and is now trading at $27.10. View the best growth stocks for 2024 here. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) issued its quarterly earnings data on Wednesday, July, 31st. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.37. The company earned $92.27 million during the quarter, compared to analyst estimates of $67.20 million. CareDx had a negative net margin of 53.73% and a negative trailing twelve-month return on equity of 53.65%. Who are CareDx's major shareholders? Top institutional shareholders of CareDx include ARK Investment Management LLC (10.95%), Sumitomo Mitsui Trust Holdings Inc. (4.95%), Millennium Management LLC (4.11%) and D. E. Shaw & Co. Inc. (3.32%). Insiders that own company stock include Reginald Seeto, Peter Maag, Alexander L Johnson, Michael Goldberg, Grace Colon, Ankur Dhingra and George Bickerstaff. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA) and Enphase Energy (ENPH). This page (NASDAQ:CDNA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CareDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDNA Stock Alerts